How Newer Diabetes Drugs Like GLP-1 Agonists Also Protect the Heart | Research

The takeaway

GLP-1 receptor agonists and SGLT-2 inhibitors show cardiovascular benefits in type 2 diabetes beyond blood sugar control, attributed to their effects on multiple metabolic risk factors including blood pressure, weight, and lipids.

80% of T2DM deaths are cardiovascular
Cardiovascular disease accounts for the vast majority of deaths in type 2 diabetes, making the cardiovascular benefits of GLP-1 RAs potentially more impactful than their glucose-lowering effects.

What the researchers found

The review establishes that hyperglycemia alone plays a limited role in cardiovascular disease progression in T2DM — metabolic risk factors like insulin resistance, hypertension, obesity, and dyslipidemia are the major drivers. GLP-1 receptor agonists and SGLT-2 inhibitors demonstrated cardiovascular benefits in their safety trials, attributed to diverse extra-pancreatic effects beyond glucose control.

These benefits include reductions in blood pressure, body weight, and lipid abnormalities. The review proposes studying combinations of GLP-1 RAs, SGLT-2 inhibitors, and pioglitazone in high-risk diabetic patients and even in non-diabetic patients with insulin resistance for potential cardiovascular protection.

Why it matters

This review captures a pivotal shift in diabetes treatment philosophy — from focusing solely on blood sugar control to addressing the broader metabolic syndrome that drives cardiovascular death. Understanding that GLP-1 agonists work through multiple cardiovascular protective mechanisms beyond glucose lowering has fundamentally changed how these drugs are prescribed and has expanded their use to patients whose primary need is cardiovascular protection.

How the study worked

This is a narrative review article discussing the cardiovascular benefits observed in major cardiovascular outcome trials (CVOTs) of GLP-1 receptor agonists and SGLT-2 inhibitors. The review synthesizes evidence from clinical trials and mechanistic studies to explain the cardiovascular protective effects of these newer diabetes medications.

What this study cannot tell us

Published in 2017, this review predates many subsequent cardiovascular outcome trials and guideline updates. The evidence for some GLP-1 agonists was limited at the time of writing. The review is narrative rather than systematic, introducing potential selection bias. Long-term cardiovascular outcomes (beyond trial durations) were not available. Cost-effectiveness analyses were not included despite the high cost of newer agents.

How to read the evidence

This is a narrative review synthesizing evidence from major cardiovascular outcome trials. While the individual trials provide strong evidence, the review format introduces potential selection bias. It provides a useful overview of the evidence landscape as of 2017.

When this study was published

Published in 2017, this review captured early enthusiasm about GLP-1 RA cardiovascular benefits. Since then, additional trials have substantially strengthened the evidence, and clinical guidelines have been updated to recommend GLP-1 RAs for cardiovascular risk reduction in T2DM.

The bigger picture

This review was written at a turning point in diabetes management. The cardiovascular outcome trials referenced here — including LEADER (liraglutide) and SUSTAIN-6 (semaglutide) — transformed GLP-1 agonists from simple diabetes drugs into cardiovascular protective agents. The insight that metabolic risk factors, not glucose levels, drive heart disease in diabetes has reshaped clinical guidelines worldwide and driven the expansion of GLP-1 RAs into obesity treatment.

Questions still open

Would combining GLP-1 RAs with SGLT-2 inhibitors provide additive cardiovascular protection beyond either alone?
Should GLP-1 agonists be prescribed for cardiovascular protection in non-diabetic patients with insulin resistance?
How do the cardiovascular benefits of different GLP-1 agonists compare to each other?

Common questions

Why do GLP-1 drugs protect the heart if blood sugar isn't the main problem?

While GLP-1 agonists do lower blood sugar, their heart benefits come from addressing other risk factors: they reduce blood pressure, promote weight loss, improve cholesterol profiles, and have direct anti-inflammatory effects on blood vessels. Since these metabolic factors — not high blood sugar — drive most heart disease in diabetes, the multi-target approach is what makes GLP-1 drugs cardiovascularly protective.

Should everyone with type 2 diabetes take a GLP-1 drug for heart protection?

This review supports using GLP-1 agonists in T2DM patients at elevated cardiovascular risk. Current guidelines have since confirmed this recommendation. However, factors like cost, side effects, and individual risk profiles should be considered. Not every diabetic patient needs these specific drugs.

Read the original research

Cardiovascular benefits of the newer medications for treating type 2 diabetes mellitus.

Journal of thoracic disease, 9(7), 2124-2134

View on PubMed ↗Publisher’s paper ↗

Citation

Yandrapalli, Srikanth; Aronow, Wilbert S. (2017). Cardiovascular benefits of the newer medications for treating type 2 diabetes mellitus.. Journal of thoracic disease, 9(7), 2124-2134. https://doi.org/10.21037/jtd.2017.06.70